SI3587418T1 - Zaviralci creb vezavnega proteina (cbp) - Google Patents
Zaviralci creb vezavnega proteina (cbp)Info
- Publication number
- SI3587418T1 SI3587418T1 SI201930136T SI201930136T SI3587418T1 SI 3587418 T1 SI3587418 T1 SI 3587418T1 SI 201930136 T SI201930136 T SI 201930136T SI 201930136 T SI201930136 T SI 201930136T SI 3587418 T1 SI3587418 T1 SI 3587418T1
- Authority
- SI
- Slovenia
- Prior art keywords
- cbp
- binding protein
- protein inhibitors
- creb binding
- creb
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862692593P | 2018-06-29 | 2018-06-29 | |
| PCT/US2018/051235 WO2019055877A1 (en) | 2017-09-15 | 2018-09-14 | TETRAHYDROIMIDAZO QUINOLINE COMPOSITIONS AS INHIBITORS OF CBP / P300 |
| PCT/US2018/051214 WO2019055869A1 (en) | 2017-09-15 | 2018-09-14 | TETRAHYDROIMIDAZO QUINOLINE COMPOSITIONS AS INHIBITORS OF CBP / P300 |
| US201962819490P | 2019-03-15 | 2019-03-15 | |
| PCT/US2019/039936 WO2020006483A1 (en) | 2018-06-29 | 2019-06-28 | Inhibiting creb binding protein (cbp) |
| US16/457,596 US10870648B2 (en) | 2018-06-29 | 2019-06-28 | Inhibiting CREB binding protein (CBP) |
| EP19183741.8A EP3587418B1 (en) | 2018-06-29 | 2019-07-01 | Inhibitors of creb binding protein (cbp) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SI3587418T1 true SI3587418T1 (sl) | 2022-03-31 |
Family
ID=68987627
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI201930136T SI3587418T1 (sl) | 2018-06-29 | 2019-07-01 | Zaviralci creb vezavnega proteina (cbp) |
Country Status (26)
| Country | Link |
|---|---|
| US (3) | US10870648B2 (enExample) |
| EP (1) | EP3998266A1 (enExample) |
| JP (4) | JP6781806B2 (enExample) |
| KR (2) | KR20250067962A (enExample) |
| CN (2) | CN116178369A (enExample) |
| AU (3) | AU2019295790B2 (enExample) |
| BR (1) | BR112020026783A2 (enExample) |
| CA (1) | CA3105099A1 (enExample) |
| CY (1) | CY1124762T1 (enExample) |
| DK (1) | DK3587418T3 (enExample) |
| ES (1) | ES2900105T3 (enExample) |
| HR (1) | HRP20211698T1 (enExample) |
| HU (1) | HUE056885T2 (enExample) |
| IL (3) | IL313466B2 (enExample) |
| LT (1) | LT3587418T (enExample) |
| MA (1) | MA50675B1 (enExample) |
| MX (2) | MX2023013508A (enExample) |
| PL (1) | PL3587418T3 (enExample) |
| PT (1) | PT3587418T (enExample) |
| RS (1) | RS62732B1 (enExample) |
| SA (1) | SA520420909B1 (enExample) |
| SG (1) | SG11202012767UA (enExample) |
| SI (1) | SI3587418T1 (enExample) |
| SM (1) | SMT202100636T1 (enExample) |
| WO (1) | WO2020006483A1 (enExample) |
| ZA (2) | ZA202100509B (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2023013508A (es) * | 2018-06-29 | 2023-12-13 | Forma Therapeutics Inc | Inhibicion de la proteina de union a creb (cbp). |
| EP3938365A4 (en) * | 2019-03-15 | 2023-01-25 | Forma Therapeutics, Inc. | COMPOSITIONS AND METHODS OF TREATMENT OF ANDROGEN RECEPTOR POSITIVE FORMS OF CANCER |
| US12351577B2 (en) | 2019-03-15 | 2025-07-08 | Forma Therapeutics, Inc. | Inhibiting cyclic AMP-responsive element-binding protein (CREB) |
| EP4171556A1 (en) | 2020-06-25 | 2023-05-03 | Tolremo Therapeutics AG | A combination of a cbp/p300 bromodomain inhibitor and an egfr inhibitor for use in treating egfr-mutant nsclc |
| US12472179B2 (en) | 2020-06-25 | 2025-11-18 | Tolremo Therapeutics Ag | Combination of a CBP/p300 bromodomain inhibitor and a KRAS inhibitor for the treatment of cancer |
| US11795168B2 (en) | 2020-09-23 | 2023-10-24 | Forma Therapeutics, Inc. | Inhibiting cyclic amp-responsive element-binding protein (CREB) binding protein (CBP) |
| US11801243B2 (en) | 2020-09-23 | 2023-10-31 | Forma Therapeutics, Inc. | Bromodomain inhibitors for androgen receptor-driven cancers |
Family Cites Families (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4404207A (en) | 1981-11-06 | 1983-09-13 | Riker Laboratories, Inc. | Antimicrobial 8-substituted benzo [IJ]quinolizines |
| US5138089A (en) * | 1986-06-27 | 1992-08-11 | The Procter & Gamble Company | Chromophores, sunscreen compositions and methods for preventing sunburn |
| WO1995020589A1 (en) | 1994-01-28 | 1995-08-03 | Cell Therapeutics, Inc. | Cell signaling inhibitors |
| US6011029A (en) | 1996-02-26 | 2000-01-04 | Bristol-Myers Squibb Company | Inhibitors of farnesyl protein transferase |
| US6455564B1 (en) | 1999-01-06 | 2002-09-24 | Pharmacia & Upjohn Company | Method of treating sexual disturbances |
| US7101869B2 (en) | 1999-11-30 | 2006-09-05 | Pfizer Inc. | 2,4-diaminopyrimidine compounds useful as immunosuppressants |
| US7345051B2 (en) | 2000-01-31 | 2008-03-18 | Genaera Corporation | Mucin synthesis inhibitors |
| KR100865775B1 (ko) | 2000-11-20 | 2008-10-29 | 메르크 파텐트 게엠베하 | 키랄 광이성질성 화합물 |
| CA2463136A1 (en) | 2001-10-17 | 2003-04-24 | Raymond Andersen | Ship 1 modulators |
| EP1460067A4 (en) | 2001-11-26 | 2005-12-07 | Takeda Pharmaceutical | BICYCLIC DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE |
| HUP0203976A3 (en) | 2002-11-15 | 2004-08-30 | Sanofi Aventis | Adenozine a3 receptors, process for their preparation and pharmaceutical compositions containing them |
| TWI322012B (en) | 2002-12-20 | 2010-03-21 | Organon Nv | Tetrahydroquinoline derivatives |
| IN2003CH00929A (enExample) | 2003-11-13 | 2008-10-06 | ||
| US20080188527A1 (en) | 2003-12-23 | 2008-08-07 | Cashman John R | Synthetic Compounds and Derivatives as Modulators of Smoking or Nicotine Ingestion and Lung Cancer |
| US7897607B2 (en) | 2004-04-07 | 2011-03-01 | Takeda Pharmaceutical Company Limited | Cyclic compounds |
| WO2005105814A1 (en) | 2004-04-28 | 2005-11-10 | Incyte Corporation | Tetracyclic inhibitors of janus kinases |
| JP2009520038A (ja) | 2005-12-19 | 2009-05-21 | ジェネンテック・インコーポレーテッド | ピリミジンキナーゼインヒビター |
| US20070203236A1 (en) | 2006-01-11 | 2007-08-30 | Smith Jeffrey W | Novel antagonists of the human fatty acid synthase thioesterase |
| WO2007133653A2 (en) | 2006-05-09 | 2007-11-22 | Hemaquest Pharmaceuticals, Inc. | Methods for treating blood disorders |
| EP1878724A1 (en) | 2006-07-15 | 2008-01-16 | sanofi-aventis | A regioselective palladium catalyzed synthesis of benzimidazoles and azabenzimidazoles |
| CA2574531C (en) | 2007-01-19 | 2016-10-25 | The University Of British Columbia | Hat acetylation promoters and uses of compositions thereof in promoting immunogenicity |
| US8476458B2 (en) | 2007-06-21 | 2013-07-02 | The Wistar Institute | Methods and compositions for modulating P300/CBP activity |
| KR20100023907A (ko) | 2007-06-26 | 2010-03-04 | 사노피-아벤티스 | 벤즈이미다졸 및 아자벤즈이미다졸의 위치선택적 구리 촉매화 합성 |
| EP2172453A4 (en) | 2007-06-27 | 2010-12-22 | Taisho Pharmaceutical Co Ltd | CONNECTION WITH 11-β-HSD1 INHIBITING ACTIVITY |
| TW200930369A (en) | 2007-11-15 | 2009-07-16 | Astrazeneca Ab | Bis-(sulfonylamino) derivatives in therapy |
| AR072008A1 (es) | 2008-06-13 | 2010-07-28 | Merck & Co Inc | Compuestos heterobiciclicos como agentes de inhibicion de quinasa p38 |
| UA105005C2 (uk) | 2008-06-16 | 2014-04-10 | Юніверсіті Оф Теннессі Рісерч Фаундейшн | Сполуки для лікування раку |
| WO2010110380A1 (ja) * | 2009-03-27 | 2010-09-30 | 興和株式会社 | 縮合ピペリジン化合物及びこれを含有する医薬 |
| WO2010118208A1 (en) | 2009-04-09 | 2010-10-14 | Exelixis, Inc. | Benzoxazepin-4- (5h) -yl derivatives and their use to treat cancer |
| SG175045A1 (en) | 2009-04-15 | 2011-11-28 | Jw Pharmaceutical Corp | Novel compounds of reverse-turn mimetics, method for manufacturing the same and use thereof |
| BRPI1010896A2 (pt) | 2009-05-26 | 2019-09-24 | Exelixis Inc | benzoxazepinas como inibidores de pi3k/mtor e métodos de seus usos e fabricação |
| WO2010138490A1 (en) | 2009-05-26 | 2010-12-02 | Exelixis, Inc. | Benzoxazepines as inhibitors of mtor and methods of their use and manufacture |
| WO2011085039A2 (en) | 2010-01-05 | 2011-07-14 | The Johns Hopkins University | Use of histone acetyltransferase inhibitors as novel anti-cancer therapies |
| EP3064204A1 (en) | 2010-03-01 | 2016-09-07 | GTx, Inc. | Compounds for treatment of cancer |
| JP5911476B2 (ja) * | 2010-05-26 | 2016-04-27 | スノビオン プハルマセウトイカルス インコーポレイテッド | ヘテロアリール化合物及びその使用方法 |
| US8906943B2 (en) | 2010-08-05 | 2014-12-09 | John R. Cashman | Synthetic compounds and methods to decrease nicotine self-administration |
| JP5937102B2 (ja) | 2010-12-14 | 2016-06-22 | エレクトロフォレティクス リミテッド | カゼインキナーゼ１デルタ（ｃｋ１デルタ）阻害剤 |
| US8765978B2 (en) | 2010-12-16 | 2014-07-01 | Transitions Optical, Inc. | Method of making indeno-fused naphthol materials |
| EP2678050B1 (en) | 2011-02-24 | 2020-10-14 | Emory University | Noggin blocking compositions for ossification and methods related thereto |
| TWI478908B (zh) | 2011-07-01 | 2015-04-01 | Gilead Sciences Inc | 作為離子通道調節劑之稠合雜環化合物 |
| GB201111705D0 (en) | 2011-07-07 | 2011-08-24 | Takeda Pharmaceutical | Compounds and their use |
| WO2013148114A1 (en) | 2012-03-30 | 2013-10-03 | University Of Florida Research Foundation, Inc. | P300/cbp inhibitors and methods of use |
| US9211333B2 (en) | 2012-06-05 | 2015-12-15 | Hong Kong Baptist University | Anti-cancer agents synthesized based on miliusane compounds |
| EP2897962A1 (en) | 2012-09-21 | 2015-07-29 | Advinus Therapeutics Limited | Substituted fused tricyclic compounds, compositions and medicinal applications thereof |
| RU2543485C2 (ru) | 2013-02-26 | 2015-03-10 | Андрей Александрович Иващенко | Гетероциклические агонисты рецепторов желчных кислот tgr5, фармацевтическая композиция, способы их получения и применения |
| TWI527811B (zh) | 2013-05-09 | 2016-04-01 | 吉李德科學股份有限公司 | 作爲溴結構域抑制劑的苯並咪唑衍生物 |
| WO2015004533A2 (en) | 2013-06-21 | 2015-01-15 | Zenith Epigenetics Corp. | Novel substituted bicyclic compounds as bromodomain inhibitors |
| SG11201510409QA (en) | 2013-06-21 | 2016-01-28 | Zenith Epigenetics Corp | Novel bicyclic bromodomain inhibitors |
| BR112016001457A2 (pt) | 2013-07-25 | 2017-08-29 | Dana Farber Cancer Inst Inc | Inibidores de fatores de transcrição e usos dos mesmos |
| DE102013215912B3 (de) | 2013-08-12 | 2015-02-26 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Farbneutral beschichteter kupferhaltiger Gegenstand, Verfahren zu dessen Herstellung sowie Verwendung einer entsprechenden farbneutralen Beschichtung |
| UY35834A (es) | 2013-11-14 | 2015-05-29 | Bristol Myers Squibb Company Una Corporación Del Estado De Delaware | Piperazinas de pirazolo sustituido como inhibidores de caseína quinasa 1 delta y epsilon |
| US9422281B2 (en) | 2013-11-18 | 2016-08-23 | Forma Therapeutics, Inc. | Benzopiperazine compositions as BET bromodomain inhibitors |
| WO2015074064A2 (en) * | 2013-11-18 | 2015-05-21 | Bair Kenneth W | Tetrahydroquinoline compositions as bet bromodomain inhibitors |
| CN107073125A (zh) | 2014-09-19 | 2017-08-18 | 基因泰克公司 | Cbp/ep300和bet抑制剂用于治疗癌症的用途 |
| CN107531690B (zh) * | 2014-11-27 | 2020-11-06 | 基因泰克公司 | 用作CBP和/或EP300抑制剂的4,5,6,7-四氢-1H-吡唑并[4,3-c]吡啶-3-胺化合物 |
| BR112017014770A2 (pt) | 2015-01-08 | 2018-01-16 | Advinus Therapeutics Ltd | compostos bicíclicos, composições e aplicações médicas dos mesmos |
| WO2016128908A1 (en) | 2015-02-12 | 2016-08-18 | Advinus Therapeutics Limited | Bicyclic compounds, compositions and medicinal applications thereof |
| GB201506658D0 (en) | 2015-04-20 | 2015-06-03 | Cellcentric Ltd | Pharmaceutical compounds |
| GB201506660D0 (en) | 2015-04-20 | 2015-06-03 | Cellcentric Ltd | Pharmaceutical compounds |
| WO2017197056A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | Bromodomain targeting degronimers for target protein degradation |
| CA3024556A1 (en) | 2016-05-12 | 2017-11-16 | The Regents Of The University Of Michigan | Ash1l inhibitors and methods of treatment therewith |
| JP7160688B2 (ja) | 2016-05-24 | 2022-10-25 | ジェネンテック， インコーポレイテッド | Ｃｂｐ／ｅｐ３００の複素環式インヒビターおよびがんの処置におけるそれらの使用 |
| GB201617630D0 (en) | 2016-10-18 | 2016-11-30 | Cellcentric Ltd | Pharmaceutical compounds |
| GB201617627D0 (en) | 2016-10-18 | 2016-11-30 | Cellcentric Ltd | Pharmaceutical compounds |
| TW202332436A (zh) * | 2017-04-18 | 2023-08-16 | 美商塞爾基因定量細胞研究公司 | 治療用化合物 |
| TWI846350B (zh) * | 2017-09-15 | 2024-06-21 | 美商佛瑪治療公司 | 作為ＣＢＰ／ｐ３００抑制劑之四氫－咪唑並喹啉化合物 |
| MX2023013508A (es) * | 2018-06-29 | 2023-12-13 | Forma Therapeutics Inc | Inhibicion de la proteina de union a creb (cbp). |
-
2019
- 2019-06-28 MX MX2023013508A patent/MX2023013508A/es unknown
- 2019-06-28 BR BR112020026783-0A patent/BR112020026783A2/pt unknown
- 2019-06-28 KR KR1020257014745A patent/KR20250067962A/ko active Pending
- 2019-06-28 CN CN202211658329.8A patent/CN116178369A/zh active Pending
- 2019-06-28 CN CN201980050022.XA patent/CN112513038B/zh active Active
- 2019-06-28 SG SG11202012767UA patent/SG11202012767UA/en unknown
- 2019-06-28 IL IL313466A patent/IL313466B2/en unknown
- 2019-06-28 IL IL321337A patent/IL321337A/en unknown
- 2019-06-28 AU AU2019295790A patent/AU2019295790B2/en active Active
- 2019-06-28 WO PCT/US2019/039936 patent/WO2020006483A1/en not_active Ceased
- 2019-06-28 US US16/457,596 patent/US10870648B2/en active Active
- 2019-06-28 KR KR1020217002866A patent/KR102805503B1/ko active Active
- 2019-06-28 IL IL279734A patent/IL279734B2/en unknown
- 2019-06-28 CA CA3105099A patent/CA3105099A1/en active Pending
- 2019-06-28 MX MX2020014303A patent/MX2020014303A/es unknown
- 2019-07-01 RS RS20211321A patent/RS62732B1/sr unknown
- 2019-07-01 ES ES19183741T patent/ES2900105T3/es active Active
- 2019-07-01 PL PL19183741T patent/PL3587418T3/pl unknown
- 2019-07-01 DK DK19183741.8T patent/DK3587418T3/da active
- 2019-07-01 LT LTEP19183741.8T patent/LT3587418T/lt unknown
- 2019-07-01 SI SI201930136T patent/SI3587418T1/sl unknown
- 2019-07-01 JP JP2019123100A patent/JP6781806B2/ja active Active
- 2019-07-01 HU HUE19183741A patent/HUE056885T2/hu unknown
- 2019-07-01 PT PT191837418T patent/PT3587418T/pt unknown
- 2019-07-01 HR HRP20211698TT patent/HRP20211698T1/hr unknown
- 2019-07-01 MA MA50675A patent/MA50675B1/fr unknown
- 2019-07-01 EP EP21193994.7A patent/EP3998266A1/en active Pending
- 2019-07-01 SM SM20210636T patent/SMT202100636T1/it unknown
-
2020
- 2020-05-28 JP JP2020093126A patent/JP7017801B2/ja active Active
- 2020-06-08 US US16/946,159 patent/US11254674B2/en active Active
- 2020-12-17 JP JP2020209005A patent/JP2021042255A/ja not_active Withdrawn
- 2020-12-28 SA SA520420909A patent/SA520420909B1/ar unknown
-
2021
- 2021-01-25 ZA ZA2021/00509A patent/ZA202100509B/en unknown
- 2021-11-22 CY CY20211101010T patent/CY1124762T1/el unknown
-
2022
- 2022-02-10 US US17/669,112 patent/US12378242B2/en active Active
- 2022-09-23 ZA ZA2022/10560A patent/ZA202210560B/en unknown
-
2023
- 2023-09-05 AU AU2023226653A patent/AU2023226653B2/en active Active
-
2025
- 2025-03-21 JP JP2025046918A patent/JP2025094157A/ja active Pending
- 2025-07-29 AU AU2025210762A patent/AU2025210762A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL282179A (en) | Protein tyrosine phosphatase inhibitors | |
| IL286462A (en) | Protein tyrosine phosphatase inhibitors | |
| SI3587418T1 (sl) | Zaviralci creb vezavnega proteina (cbp) | |
| EP4241847C0 (en) | ENHANCED CELL TARGETING BINDING MOLECULE | |
| EP3630783A4 (en) | PENICILLIN-BINDING PROTEIN INHIBITORS | |
| IL281962A (en) | Il-12 heterodimeric fc-fusion proteins | |
| EP3630782A4 (en) | Penicillin-binding protein inhibitors | |
| EP3621994A4 (en) | MESOTHELIN BINDING PROTEINS | |
| EP3932338C0 (en) | TURNSTILE | |
| EP3833350A4 (en) | Pyrrolopyrimidine itk inhibitors | |
| EP3595720A4 (en) | ANTIBODIES BINDING TO VISTA AT AN ACID PH | |
| IL279355A (en) | Anti-steap1 antigen-binding protein | |
| EP3802551A4 (en) | Penicillin-binding protein inhibitors | |
| EP3902805A4 (en) | CYCLINE-DEPENDENT KINASE INHIBITORS | |
| IL280950A (en) | Inhibitors of keap1-nrf2 protein-protein interaction | |
| EP3790871C0 (en) | FURIN INHIBITORS | |
| EP3804707A4 (en) | KINASE INHIBITOR | |
| EP3661961A4 (en) | ANTIBODIES BINDING TO ACTIVE ALPHA-SYNUCLEIN | |
| EP3848293A4 (en) | BINDING MACHINE | |
| IL284317A (en) | Pseudofab-based multispecific binding proteins | |
| EP3587707C0 (en) | BONDING MACHINE | |
| EP3765265A4 (en) | BINDER | |
| EP3848537C0 (en) | LINKING MACHINE | |
| EP3848292C0 (en) | LINKING MACHINE | |
| EP3774922A4 (en) | BINDING MOLECULES INVOLVING CELLS |